Clinical Trial Update: A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating self-administered subcutaneous belimumab in healthy subjects to estimate relative bioavailability, tolerability, and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• BENLYSTA (belimumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED